Given that the Type II receptors of the TGFβ family have been identified in genomic studies as driver protein kinases in about 5–15% of cancers [141], identification of all their substrates will likely shed light on additional mechanisms including EMT in cancer. This evidence concerns the gene TGFB1 and cancer.